The results of Ryuge's study suggest that Nestin expression may be utilized as a possible marker to identify individuals who should receive adjuvant chemotherapy and is a prognostic indicator of poorer survival in resected NSCLC patients.50 The gene discussed is NES; the disease is non-small cell lung carcinoma.